Literature DB >> 25674090

Mysteries of type I IFN response: benefits versus detriments.

Yoichi Furuya1, Herbert P Ludewick1, Arno Müllbacher2.   

Abstract

Entities:  

Keywords:  bacterial; type I interferons; vaccine adjuvant; viral

Year:  2015        PMID: 25674090      PMCID: PMC4309204          DOI: 10.3389/fimmu.2015.00021

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


× No keyword cloud information.
Successful containment of infection is dependent on both innate and adaptive immune responses. Cytokines are essential components of both of these systems. In particular, type I interferons (IFN-I) are important components of early innate immunity against infections. However, the production of IFN-I could serve as a double-edged sword, in that it could help eliminate infections or in certain instances enhance host’s susceptibility to infections. For example, IFN-I provide early resistance against acute viral infections, but are detrimental to the host during certain bacterial infections and chronic viral infections. This Research Topic presents seven articles that address the biological roles of IFN-Is in host immunity and various contexts (e.g., autoimmunity, cancer, viral/bacterial infections, IFN-I therapy, etc.) where IFN-Is could either serve to control or exacerbate disease. The original research performed by Babb et al. investigates the potential adjuvant activity of gamma-irradiated influenza (1). They demonstrate that co-vaccination with gamma-irradiated-influenza virus and poorly immunogenic inactivated Semliki forest virus (SFV) results in enhanced SFV-specific antibody responses without compromising humoral immunity against influenza infections. They have previously shown that gamma-irradiation destroys the ability of SFV but not influenza A virus to elicit strong IFN-I responses (2). Thus, it is likely that the adjuvant activity of gamma-irradiated influenza virus is attributable to its potency of IFN-I induction. These authors speculate that gamma-irradiated influenza virus may therefore be exploited as an adjuvant to improve the efficacy of poorly immunogenic vaccines owing to its ability to stimulate IFN-I production. The potent immune activating properties of IFN-I can also be detrimental during viral infection, particularly for viruses that establish chronic infection. This certainly is the case for human or simian immunodeficiency virus (HIV/SIV) infection in non-natural hosts. As discussed by Tomasello et al. (3) and Furuya et al. (4), IFN-I induced during HIV infections may play a pathogenic role in driving chronic immune activation associated with CD4+ T cell depletion and loss of T cell function. Indeed, a strong correlation exists between chronic low level productions of IFN-I and disease progression in non-natural hosts. Thus, Furuya et al. hypothesize that regulatory mechanisms must exist in natural hosts that actively suppress IFN-I responses despite viral replication (4). It is speculated that understanding how the host can co-exist with HIV without generating an IFN-I response will be crucial in developing therapeutic interventions that can prevent or dampen progression to an acquired immune deficiency syndrome (AIDS). Perhaps, as pointed out by Tomasello et al., the more important question that needs to be addressed first is whether a causal link exists between low levels of IFN-I signaling and the development of AIDS in non-natural hosts or, rather, the up-regulation of IFN-stimulated genes simply a marker of disease progression. The pathogenic role of IFN-I is more widely observed in bacterial infections. For example, the facultative intracellular bacterium Francisella tularensis is less virulent in mice deficient in IFN-I receptors (5, 6). Furuya et al. propose in an opinion article that the detrimental role of IFN-I during pulmonary tularemia may be linked to its suppressive effects on neutrophil recruitment, a response that may be protective against respiratory Francisella tularensis infection (7). The role of neutrophils during pulmonary tularemia has yet to be fully defined, but it is likely that both the magnitude and timing of cellular recruitment to the lung will determine whether neutrophils promote bacterial clearance or contribute to immunopathology. In three review articles, the mechanisms that have been proposed to explain the IFN-I-mediated increases in bacterial infection susceptibility are discussed. The review article by Eshleman et al. focuses on the suppressive effects of IFN-I on myeloid cells during intracellular bacterial infections (8). These authors also emphasize that IFN-I can exert a positive anti-inflammatory effect in a number of autoimmune diseases and that this is mediated by the suppression of myeloid cell inflammatory responses. The review article from Dhariwala et al. describes multiple pathways of IFN-I-dependent cell deaths that may aid bacteria escape phagocytosis and thereby contributes to bacterial pathogenesis (9). Indeed, as the author pointed out, bacterial pathogens that benefits from IFN-I signaling are often facultative intracellular bacteria. The final review by Wijesundara et al. highlights pathological contexts in which IFN-I could be exploited in therapy and vaccine design with a particular emphasis on IFN-epsilon (10). IFN-epsilon appears to have both overlapping and distinct functions compared to IFN-alpha and -beta, and therefore, the author urge the need of evaluating contribution of the different members of IFN-I to fully exploit its beneficial effects. Despite IFN-I being perhaps the most studied cytokine, their immunoregulatory roles are not fully understood. As is evident from the articles presented in this Research Topic, the role played by IFN-I is highly context-dependent and can be both beneficial and detrimental. Further research is clearly required in order for us to selectively harness the protective role of IFN-I while suppressing its damaging effects.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  10 in total

1.  Type I IFN signaling constrains IL-17A/F secretion by gammadelta T cells during bacterial infections.

Authors:  Thomas Henry; Girish S Kirimanjeswara; Thomas Ruby; Jonathan W Jones; Kaitian Peng; Magali Perret; Lena Ho; John-Demian Sauer; Yoichiro Iwakura; Dennis W Metzger; Denise M Monack
Journal:  J Immunol       Date:  2010-02-22       Impact factor: 5.422

Review 2.  Mucosal immunopathogenesis of Francisella tularensis.

Authors:  Dennis W Metzger; Chandra Shekhar Bakshi; Girish Kirimanjeswara
Journal:  Ann N Y Acad Sci       Date:  2007-03-29       Impact factor: 5.691

3.  Gamma-irradiated influenza virus uniquely induces IFN-I mediated lymphocyte activation independent of the TLR7/MyD88 pathway.

Authors:  Yoichi Furuya; Jennifer Chan; En-Chi Wan; Aulikki Koskinen; Kerrilyn R Diener; John D Hayball; Matthias Regner; Arno Müllbacher; Mohammed Alsharifi
Journal:  PLoS One       Date:  2011-10-05       Impact factor: 3.240

4.  Gamma-Irradiated Influenza A Virus Provides Adjuvant Activity to a Co-Administered Poorly Immunogenic SFV Vaccine in Mice.

Authors:  Rachelle Babb; Jennifer Chan; Jasmine E Khairat; Yoichi Furuya; Mohammed Alsharifi
Journal:  Front Immunol       Date:  2014-06-10       Impact factor: 7.561

Review 5.  Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types.

Authors:  Elena Tomasello; Emeline Pollet; Thien-Phong Vu Manh; Gilles Uzé; Marc Dalod
Journal:  Front Immunol       Date:  2014-10-30       Impact factor: 7.561

Review 6.  Bacterial programming of host responses: coordination between type I interferon and cell death.

Authors:  Miqdad O Dhariwala; Deborah M Anderson
Journal:  Front Microbiol       Date:  2014-10-28       Impact factor: 5.640

Review 7.  Type I interferons in bacterial infections: taming of myeloid cells and possible implications for autoimmunity.

Authors:  Emily M Eshleman; Laurel L Lenz
Journal:  Front Immunol       Date:  2014-09-11       Impact factor: 7.561

Review 8.  Unraveling the convoluted biological roles of type I interferons in infection and immunity: a way forward for therapeutics and vaccine design.

Authors:  Danushka Kumara Wijesundara; Yang Xi; Charani Ranasinghe
Journal:  Front Immunol       Date:  2014-08-29       Impact factor: 7.561

Review 9.  Does Type I Interferon Limit Protective Neutrophil Responses during Pulmonary Francisella Tularensis Infection?

Authors:  Yoichi Furuya; Donald Steiner; Dennis W Metzger
Journal:  Front Immunol       Date:  2014-07-23       Impact factor: 7.561

Review 10.  The Curious Case of Type I IFN and MxA: Tipping the Immune Balance in AIDS.

Authors:  Andrea Kinga Marias Furuya; Hamayun J Sharifi; Carlos M C de Noronha
Journal:  Front Immunol       Date:  2014-09-02       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.